Hepatiq Inc.

Irvine,  CA 
United States
  • Booth: 2097

HEPATIQ® is The Ultimate Liver Test™ as it provides six indices of liver disease from a single scan including quantitative liver function.

HEPATIQ® is The Ultimate Liver Test™ as it provides six indices of liver disease from a single scan: quantitative liver function, fatty liver disease/steatohepatitis, portal hypertension, alcoholic hepatitis, fibrosis stage and variceal size.[1-23]
Not only does HEPATIQ provide six indices from a single test, it is the only product on the market that precisely and non-invasively quantifies liver function. Other techniques such as biopsies, elastography and blood tests estimate or score liver fibrosis but do not quantify function.

Quantitative liver function (PHM) can be reduced by infections, alcohol and fat buildup that cause the accumulation of fibrosis or scar tissue. The liver can regenerate new functioning nodules, and blood flow to the liver may increase, providing some mitigation.

A large, badly scarred, stiff liver can have normal function (PHM>100) [4] if there are enough functional nodules. Once a patient’s PHM drops below 75, they may decompensate, that is, develop clinical problems. [5,6,9,12,17,18,22]

If their PHM falls below 60, they may die if not transplanted soon. [8,13,16] If patients are treated and chronic liver injury is controlled, their PHM may improve.

Brands: Biopsies, elastography and blood tests estimate or score liver fibrosis. Patient outcomes are determined by residual liver function, not the extent of fibrosis. This was established in the 8 year HALT-C trial, which concluded that quantitative liver function may be more accurate than staging fibrosis in predicting clinical outcomes.[5,6] Subsequent clinical research has further confirmed that function outperforms fibrosis in predicting outcomes. [10,11,14,15,19,20,22]

 Show Specials

  • (Dec 03, 2022)

    We are offering new customers a six month trial of up to 50 HEPATIQ physician reports at no cost.  Let your clinical physicians know you have this capability so they will refer their liver disease patients for a liver SPECT scan (CPT 78803) which is covered by most insurance (Medicare pays approximately US$1,400).   You then use the cloud HEPATIQ software to process these images and produce the HEPATIQ report for distribution to the referring physician. 

    HEPATIQ can dramatically boost radiology revenues.  HEPATIQ is the only test that quantifies liver function.  All of the other tests on the market (blood, elastography and biopsy) estimate the extent of liver fibrosis.  Research shows that function outperforms fibrosis in the prediction of disease outcomes.  The HEPATIQ software is cleared for sale by the FDA.


    HEPATIQ provides six quantitative indices that help diagnose, stage and manage liver disease, while identifying those at risk of adverse outcomes. HEPATIQ uses existing equipment and staff to boost nuclear medicine revenues....

  • The HEPATIQ test is ordered by clinical physicians such as hepatologists, gastroenterologists, interventional radiologists, liver surgeons, oncologists and internists.

    The patient’s liver and spleen are imaged in a hospital radiology/nuclear medicine department or in an independent imaging center. The fed patient is injected with a low dose (about 5 mCi) standard Technicium-99m sulfur colloid solution.  The patient is scanned for about 20 minutes and planar and SPECT images acquired. The images are analyzed by the HEPATIQ software and a report prepared for review by the radiologist or nuclear medicine physician. The reviewing physician’s dictation together with the HEPATIQ report is distributed to the ordering clinical physician.

    HEPATIQ is cleared for sale by the U.S.A. Food and Drug Administration.

    The liver SPECT scan is reimbursed by insurance under CPT 78803 and can boost radiology revenues.

    HEPATIQ is pure software and uses existing equipment, infrastructure and staff. No capital investment is needed and only a usage fee is charged as monitored by the TRUPAS server.

    More information at www.hepatiq.com.